Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.
BACKGROUND
Activation and coagulation biomarkers were measured within the Strategies for Management of Antiretroviral Therapy (SMART) trial. Their associations with opportunistic disease (OD) in human immunodeficiency virus (HIV)-positive patients were examined.


METHODS
Inflammatory (high-sensitivity C-reactive protein [hsCRP], interleukin-6 [IL-6], amyloid-A, and amyloid-P) and coagulation (D-dimer and prothrombin-fragment 1+2) markers were determined. Conditional logistic regression analyses were used to assess associations between these biomarkers and risk of OD.


RESULTS
The 91 patients who developed an OD were matched to 182 control subjects. Patients with an hsCRP level > or =5 microg/mL at baseline had a 3.5 higher odds of OD (95% confidence interval [CI], 1.5-8.1) than did those with an hsCRP level <1 microg/mL (P=.003, by test for trend) and patients with an IL-6 level > or =3 pg/mL at baseline had a 2.4 higher odds of OD (95% CI, 1.0-5.4) than did those with an IL-6 level <1.5 pg/mL (P=.02, by test for trend). No other baseline biomarkers predicted development of an OD. Latest follow-up hsCRP level for those with an hsCRP level > or =5 microg/mL (compared with a level <1 microg/mL; odds ratio [OR], 7.6; 95% CI, 2.0-28.5; [P=.002, by test for trend), latest amyloid-A level for those with an amyloid-A level > or =6 mg/L (compared with a level <2 mg/L; OR, 3.8; 95% CI, 1.1-13.4; P=.03, by test for trend), and latest IL-6 level for those with an IL-6 level > or =3 pg/mL (compared with a level <1.5 pg/mL; OR 2.4; 95% CI, 0.7-8.8; P=.04, by test for trend) were also associated with development of an OD.


CONCLUSIONS
Higher IL-6 and hsCRP levels independently predicted development of OD. These biomarkers could provide additional prognostic information for predicting the risk of OD.
Rodger
Alison J
AJ
HIV Epidemiology and Biostatistics Group, Research Dept. of Infection and Population Health, UCL Medical School, University College London, London, UK. a.rodger@pcps.ucl.ac.uk
Fox
Zoe
Z
Lundgren
Jens D
JD
Kuller
Lewis H
LH
Boesecke
Christoph
C
Gey
Daniela
D
Skoutelis
Athanassios
A
Goetz
Matthew Bidwell
MB
Phillips
Andrew N
AN
D017088:AIDS-Related Opportunistic Infections / Q000378:metabolism*; D000328:Adult; D019380:Anti-HIV Agents; D015415:Biomarkers; D001777:Blood Coagulation / Q000502:physiology*; D002097:C-Reactive Protein / Q000378:metabolism; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007249:Inflammation / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D012307:Risk Factors; D000685:Serum Amyloid A Protein / Q000378:metabolism; D000683:Serum Amyloid P-Component / Q000378:metabolism
D019380:Anti-HIV Agents; D015415:Biomarkers; D015850:Interleukin-6; D000685:Serum Amyloid A Protein; D000683:Serum Amyloid P-Component; D002097:C-Reactive Protein
Cell Mol Life Sci. 2009 Jan;66(1):9-26
18726069
PLoS Med. 2008 Oct 21;5(10):e203
18942885
Nephrol Dial Transplant. 2002 Sep;17(9):1684-8
12198224
AIDS. 1998 Sep 10;12(13):1581-90
9764776
AIDS. 2000 May 26;14(8):951-8
10853976
BMC Cancer. 2001;1:19
11710966
Blood. 1993 Jun 15;81(12):3357-64
8507873
Br J Cancer. 2002 Dec 2;87(12):1437-44
12454774
J Infect Dis. 2000 Jan;181(1):51-7
10608750
AIDS. 2008 Feb 19;22(4):439-46
18301056
AIDS. 1991 May;5(5):505-11
1677808
Clin Exp Immunol. 2000 Apr;120(1):107-12
10759771
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Oct 1;16(2):83-92
9358102
AIDS. 2007 Oct 1;21(15):2067-75
17885297
N Engl J Med. 2000 Mar 23;342(12):836-43
10733371
J Immunol. 1990 Jan 15;144(2):480-4
2295799
Am J Kidney Dis. 2006 Jan;47(1):139-48
16377395
J Immunol. 1992 Dec 1;149(11):3727-34
1431144
N Engl J Med. 2006 Nov 30;355(22):2283-96
17135583
J Infect Dis. 2008 Apr 15;197(8):1145-55
18476293
Arch Intern Med. 2006 Jan 9;166(1):64-70
16401812
J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):346-55
11917238
Infect Immun. 1992 Oct;60(10):4245-52
1328056
HIV Clin Trials. 2008 May-Jun;9(3):177-85
18547904
J Infect Dis. 1999 Apr;179(4):843-8
10068579
J Infect Dis. 2002 Feb 15;185(4):456-62
11865397
Circulation. 2001 Feb 20;103(7):947-53
11181468
AIDS. 1998 Jun 18;12(9):1007-13
9662196
J Acquir Immune Defic Syndr. 2003 Feb 1;32(2):210-4
12571532
AIDS. 2004 Jan 2;18(1):51-8
15090829
Cancer Res. 2005 Jun 1;65(11):4673-82
15930285